Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab.
- Alice Cho,
- Bridget Bradley,
- Robert Kauffman,
- Lalita Priyamvada,
- Yevgeniy Kovalenkov,
- Ron Feldman,
- Jens Wrammert
JCI Insight 2017 Jun 15;2(12). Epub 2017 Jun 15.
Department of Pediatrics, Division of Infectious Disease.
Rituximab is a therapeutic anti-CD20 monoclonal antibody widely used to treat B cell lymphoma and autoimmune diseases, such as rheumatic arthritis, systemic lupus erythematosus, and autoimmune blistering skin diseases (AIBD). While rituximab fully depletes peripheral blood B cells, it remains unclear whether some preexisting B cell memory to pathogens or vaccines may survive depletion, especially in lymphoid tissues, and if these memory B cells can undergo homeostatic expansion during recovery from depletion. The limited data available on vaccine efficacy in this setting have been derived from rituximab-treated patients receiving concomitant chemotherapy or other potent immunosuppressants. Read More